BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28593386)

  • 1. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis.
    Klein Nulent TJW; van Es RJJ; Krijger GC; de Bree R; Willems SM; de Keizer B
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1614-1621. PubMed ID: 28593386
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
    Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
    Klein Nulent TJW; Valstar MH; Smit LA; Smeele LE; Zuithoff NPA; de Keizer B; de Bree R; van Es RJJ; Willems SM
    BMC Cancer; 2020 Jun; 20(1):519. PubMed ID: 32503460
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 68Ga-PSMA-HBED-CC and 18F-FDG PET/CT in the Evaluation of Adenoid Cystic Carcinoma-A Prospective Study.
    Shamim SA; Kumar N; Arora G; Kumar D; Pathak A; Thakkar A; Sikka K; Singh CA; Kakkar A; Bhalla AS
    Clin Nucl Med; 2023 Nov; 48(11):e509-e515. PubMed ID: 37812520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
    Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 12. Prediction of distant metastasis and survival in adenoid cystic carcinoma using quantitative
    Lim WS; Oh JS; Roh JL; Kim JS; Kim SJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Feb; 77():98-104. PubMed ID: 29362133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of peptide-based imaging agents [
    Zhang-Yin J; Provost C; Cancel-Tassin G; Rusu T; Penent M; Radulescu C; Comperat E; Cussenot O; Montravers F; Renard-Penna R; Talbot JN; Prignon A
    Nucl Med Biol; 2020; 84-85():88-95. PubMed ID: 32251995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First Clinicopathologic Evidence of a Non-PSMA-Related Uptake Mechanism for
    Rupp NJ; Umbricht CA; Pizzuto DA; Lenggenhager D; Töpfer A; Müller J; Muehlematter UJ; Ferraro DA; Messerli M; Morand GB; Huber GF; Eberli D; Schibli R; Müller C; Burger IA
    J Nucl Med; 2019 Sep; 60(9):1270-1276. PubMed ID: 30737300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Prostate-Specific Membrane Antigen PET/CT and Contrast-Enhanced Magnetic Resonance Imaging in Follow-up Assessment of Juvenile Nasal Angiofibroma-A Novel Pilot Study.
    Thakar A; Sakthivel P; Arunraj ST; Bhalla AS; Kakkar A; Kumar R; Kumar R
    Clin Nucl Med; 2020 Dec; 45(12):e498-e504. PubMed ID: 33065615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
    Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.
    Kabasakal L; Demirci E; Ocak M; Akyel R; Nematyazar J; Aygun A; Halac M; Talat Z; Araman A
    Nucl Med Commun; 2015 Jun; 36(6):582-7. PubMed ID: 25738559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.